1. In Vivo

Examining The Antibody-Drug Conjugate Pipeline

 
• By Elizabeth Cairns

An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches.   

• Source: Shutterstock

The knockback of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd.'s patritumab deruxtecan (DXd) in June, and the late-stage lung cancer misfire of AstraZeneca PLC and Daiichi Sankyo’s datopotamab DXd, shows that developing antibody-drug conjugates (ADCs) is no easy task. 

 Key Takeaways

  • 11 not-yet-approved antibody-drug conjugates are in Phase III trials.

  • A handful of antibody-drug conjugates are in Phase II trials, with several readouts coming in the next couple of years

Looking at the late-stage pipeline, next to market looks likely to be datopotamab DXd. This binds to trophoblast cell surface antigen 2 (TROP2), an antigen overexpressed in certain cancers, and delivers Daiichi Sankyo’s cytotoxic topoisomerase I inhibitor deruxtecan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.